Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas

References

• Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol. 2001;119(7):969–982.
   PubMedGoogle Scholar
• Simpson ER, Gallie B, Laperrierre N, et al. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14.
   PubMed Web of Science ®Google Scholar
• Damato B, Patel I, Campbell IR, et al. Visual acuity after Ruthenium106 brachytherapy of choroidal melanomas. Int J Radiat Oncol. 2005;63(2):392–400.
   PubMed Web of Science ®Google Scholar
• Giblin ME, Shields JA, Augsburger JJ, et al. Episcleral plaque radiotherapy for uveal melanoma. Aust N Z J Ophthalmol. 1989;17(2):153–156.
   PubMedGoogle Scholar
• Espensen CA, Jensen PK, Fog LS, et al. Ultrasonic mirror image from ruthenium plaque facilitates calculation of uveal melanoma treatment dose. Br J Ophthalmol. 2017;101(9):1206–1210.
   PubMed Web of Science ®Google Scholar
• Astrahan M. a. A patch source model for treatment planning of ruthenium ophthalmic applicators. Med Phys. 2003;30(6):1219–1228.
   PubMed Web of Science ®Google Scholar
• Rivard MJ, Coursey BM, DeWerd L., et al. Update of AAPM Task Group No. 43 Report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys. 2004;31(3):633–674.
   PubMed Web of Science ®Google Scholar
• Fowler JF. 21 Years of biologically effective dose. BJR. 2010;83(991):554–568.
   Google Scholar
• Gagne NL, Leonard KL, Huber KE, et al. BEDVH—a method for evaluating biologically effective dose volume histograms: application to eye plaque brachytherapy implants. Med Phys. 2012;39(2):976–983.
   PubMed Web of Science ®Google Scholar
• Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol. 2013;31(22):2825–2831.
   PubMed Web of Science ®Google Scholar
• Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
   PubMedGoogle Scholar
• Damato B, Patel I, Campbell IR, et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol. 2005;63(2):385–391.
   PubMed Web of Science ®Google Scholar
• Browne AW, Dandapani SV, Jennelle R, et al. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling. Brachytherapy. 2015;14(5):718–725.
   PubMed Web of Science ®Google Scholar
• Marconi DG, De Castro DG, Rebouças LM, et al. Tumor control, eye preservation, and visual outcomes of ruthenium plaque brachytherapy for choroidal melanoma. Brachytherapy. 2013;12(3):235–239.
   PubMed Web of Science ®Google Scholar
• Bergman L, Nilsson B, Lundell G, et al. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology. 2005;112(5):834–840.
   PubMed Web of Science ®Google Scholar
• Stöckel E, Eichmann M, Flühs D, et al. Dose distributions and treatment margins in ocular brachytherapy with 106Ru eye plaques. Ocul Oncol Pathol. 2018;4(2):122–128.
   PubMed Web of Science ®Google Scholar
• Summanen P, Immonen I, Heikkonen J, et al. Survival of patients and metastatic and local recurrent tumor growth in malignant melanoma of the uvea after ruthenium plaque radiotherapy. Ophthalmic Surg. 1993;24(2):82–90.
   PubMedGoogle Scholar
• Isager P, Ehlers N, Urbak SF, et al. Visual outcome, local tumour control, and eye preservation after106Ru/Rh brachytherapy for choroidal melanoma. Acta Oncol (Madr). 2006;45(3):285–293.
   PubMed Web of Science ®Google Scholar
• Dogrusöz M. Genetic Prognostication in Uveal Melanoma. Netherland: University of Leiden, 2018.
   Google Scholar
• Zloto O, Pe'er J, Frenkel S. Gender differences in clinical presentation and prognosis of uveal melanoma. Invest Ophthalmol Vis Sci. 2013;54(1):652–656.
   PubMed Web of Science ®Google Scholar
• Eckert and Ziegler BEBIG GmbH. Ophthalmic Brachytherapy 2014. 1–8. https://www.bebig.com/fileadmin/bebig_neu/user_uploads/Products/Ophthalmic_Brachytherapy/Ophthalmic_Brochure__Rev._06__English.pdf.
   Google Scholar
• Kaiserman N, Kaiserman I, Hendler K, et al. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas. Br J Ophthalmol. 2009;93(9):1167–1171.
   PubMed Web of Science ®Google Scholar
• Brualla L, Zaragoza FJ, Sauerwein W. Monte carlo simulation of the treatment of eye tumors with 106Ru plaques: a study on maximum tumor height and eccentric placement. Ocul Oncol Pathol. 2015;1(1):1–11.
   Web of Science ®Google Scholar
• Filì M, Trocme E, Bergman L, et al. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm. Br J Ophthalmol. 2020;104(1):26–27.
   PubMed Web of Science ®Google Scholar
• Puusaari I, Heikkonen J, Summanen P, et al. Iodine brachytherapy as an alternative to enucleation for large uveal melanomas. Ophthalmology. 2003;110(11):2223–2234.
   PubMed Web of Science ®Google Scholar
• Damato B, Kacperek A, Chopra M, et al. Proton beam radiotherapy of choroidal melanoma: the liverpool-clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62(5):1405–1411.
   PubMed Web of Science ®Google Scholar
• Yarovoy AA, Magaramov DA, Bulgakova ES. The comparison of ruthenium brachytherapy and simultaneous transpupillary thermotherapy of choroidal melanoma with brachytherapy alone. Brachytherapy. 2012;11(3):224–229.
   PubMed Web of Science ®Google Scholar
• Diaz CE, Capone A, Grossniklaus HE. Clinicopathologic findings in recurrent choroidal melanoma after transpupillary thermotherapy. Ophthalmology. 1998;105(8):1419–1424.
   PubMed Web of Science ®Google Scholar
• Pötter R, Van Limbergen E. Uveal Melanoma. GEC ESTRO Handb. Brachytherapy. 2nd ed., 2002. p. 591–610.
   Google Scholar
• Pötter R, Van Limbergen E, Wambersie A. Reporting in brachytherapy: dose and volume specification. GEC-ESTRO Handb. Brachytherapy. 2nd ed., 2002. p. 153–215.
   Google Scholar
• Nath R, Bice WS, Butler WM, et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Med Phys. 2009;36(11):5310–5322.
   PubMed Web of Science ®Google Scholar
• Pötter R, Tanderup K, Kirisits C, et al. EMBRACE Collaborative Group. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48–60.
   Google Scholar
• International Commission on Radiation Units and Measurements. ICRU Report 83. Prescribing, recording, and reporting photon-beam Intensity-Modulated Radiation Therapy (IMRT). J Icru. 2010;10:27–40.
   Google Scholar
• Heilemann G, Fetty L, Dulovits M, et al. Treatment plan optimization and robustness of 106Ru eye plaque brachytherapy using a novel software tool. Radiother Oncol. 2017;123(1):119–124.
   PubMed Web of Science ®Google Scholar
• Tagliaferri L, Pagliara MM, Masciocchi C, et al. Nomogram for predicting radiation maculopathy in patients treated with Ruthenium-106 plaque brachytherapy for uveal melanoma. J Contemp Brachyther. 2017;9(6):540–547.
   PubMed Web of Science ®Google Scholar
• Pagliara MM, Tagliaferri L, Azario L, et al. Ruthenium brachytherapy for uveal melanomas: factors affecting the development of radiation complications. Brachytherapy. 2018;17(2):432–438.
   PubMed Web of Science ®Google Scholar
• Espensen CA, Appelt AL, Fog LS, et al. Predicting visual acuity deterioration and radiation-induced toxicities after brachytherapy for choroidal melanomas. Cancers (Basel). 2019;11(8):1124.
   PubMed Web of Science ®Google Scholar